HMGB1 and rectal cancer: Our previous studies reported that the extent of HMGB1 release and immune cell infiltration were associated with favorable survival outcomes in locally advanced rectal cancer patients after preoperative chemoradiotherapy treatment26, suggesting that the HMGB1-TLR2/4 signaling pathway may participate in chemotherapy-induced antitumor immunity.